Table 1. Demographical and clinico-pathological features of the HCC patient population analyzed.
| Overall | <40 subset | ≥40 subset | ||
| Cohort | Headcount | 80 (100%) | 41 (51%) | 39 (49%) |
| Age | Mean±SD | 42±20 | 23±8 | 60±5 |
| Median | 39 | 22 | 61 | |
| Range | [1–83] | [1]–[39] | [40–83] | |
| Gender | Female | 33 (41%) | 18 (44%) | 15 (38.5%) |
| Male | 47 (59%) | 23 (56%) | 24 (61.5%) | |
| Sex-ratio (M:F) | 1.4 | 1.3 | 1.6 | |
| E.S. | 1,2 | 62 (77%) | 33 (80.5%) | 29 (74%) |
| 3 | 18 (23%) | 8 (19.5%) | 10 (26%) | |
| Cirrhosis | Yes | 6 (7.5%) | 2 (5%) | 4 (10%) |
| No | 74 (92.5%) | 39 (95%) | 35 (90%) | |
| HBsAg(+) | Yes | 35 (43%) | 27 (66%) | 8 (20.5%) |
| No | 45 (57%) | 14 (34%) | 31 (79.5%) | |
| HBV DNA | Yes | 59 (74%) | 36 (88%) | 23 (59%) |
| No | 21 (26%) | 5 (12%) | 16 (41%) | |
| Anti-HCV | Yes | 2 (2.5%) | 1 (2.5%) | 1 (2.5%) |
| No | 78 (97.5%) | 40 (97.5%) | 38 (97.5%) | |
| Tumor size (cm) | Mean±SD | 14±6 | 15±6 | 14±6 |
| Median | 13 | 14 | 13 | |
| Multinodularity | Yes | 25 (31%) | 14 (33%) | 11 (28%) |
| No | 55 (69%) | 27 (67%) | 28 (72%) | |
| Metastasis | Yes | 13 (16%) | 6 (14.5%) | 7 (18%) |
| No | 67 (84%) | 35 (85.5%) | 32 (82%) | |
| Recurrence | Yes | 19 (24%) | 10 (25.5%) | 9 (23%) |
| No | 61 (76%) | 31 (74.5%) | 30 (77%) | |
| Liver enzymes (IU/L) | ALP (mean±SD) | 279±240 | 280±262 | 279±222 |
| AST (mean±SD) | 109±125.5 | 129±151 | 86±85.5 | |
| GGT (mean±SD) | 62.5±71.5 | 76.5±87 | 47±45.5 | |
| AFP (ng/mL) | Median | 13,700 | 33,450 | 239 |
| IQR | 113,181 | 337,777 | 17,567 |
Abbreviations: AFP = alpha-fetoprotein; ALP = alkaline phosphatase; AST = Aspartate transaminase; E.S. = Edmonson-Steiner tumor grade; GGT = Gamma-glutamyl transpeptidase; HBV = hepatitis B virus; HBsAg = HBV surface antigen; HCC = hepatocellular carcinoma; HCV = hepatitis C virus; IQR = interquartile range; M:F = ratio of men to women; ±SD = standard deviation of the mean. <40 and ≥40 subsets are defined as patients below age 40 and those equal or above age 40, respectively. Multinodularity indicates HCC with more than one intrahepatic nodule. Recurrence indicates patients who developed a new HCC within the following 12 months after anatomic liver resection. Percentages are expressed as proportion of the total patient population for the considered parameter.